2 型糖尿病市場規模、佔有率和成長分析（按給藥途徑、分銷管道、最終用戶和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，全球 2 型糖尿病市場規模將達到 367 億美元，到 2025 年將達到 395.3 億美元，到 2033 年將達到 716.7 億美元，預測期（2026-2033 年）的複合年成長率為 7.72%。

全球第2型糖尿病市場正經歷顯著成長，主要促進因素是全球盛行率的不斷上升。對有效治療方法日益成長的需求促使製藥公司不斷創新並推出新的治療方法。其中，鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑和Glucagon-Like Peptide-1(GLP-1) 受體促效劑因其療效顯著且副作用較少，已成為首選治療方法。然而，患者對這些新治療方法的認知度仍有不足，這可能會阻礙其廣泛應用。對價格合理、先進的糖尿病管理解決方案的需求不斷成長，為市場擴張創造了巨大的機會。此外，包括行動醫療應用和雲端解決方案在內的技術進步正在革新治療方式，使全球患者更容易獲得有效的治療選擇。

全球第2型糖尿病市場促進因素

全球第二型糖尿病市場的主要促進因素之一是全球肥胖和久坐生活方式的日益普遍。肥胖率的上升導致第2型糖尿病發病率的增加，從而刺激了對有效治療方法和管理方案的需求。遺傳因素和飲食習慣進一步加劇了病例的激增，促使人們更加關注健康並採取預防措施。因此，製藥公司和醫療保健機構正大力投資於創新治療方法、監測設備和教育計畫的研發，從而建構了一個以對抗這種慢性疾病為核心的強大市場格局。

限制全球第2型糖尿病市場的因素

全球第2型糖尿病市場的主要限制因素之一是病患和醫療保健系統日益關注藥物帶來的經濟負擔。糖尿病管理藥物（包括胰島素和口服降血糖藥）價格的不斷上漲構成了一大障礙，尤其是在中低收入地區。這種經濟負擔會導致患者對處方治療的依從性降低，最終導致更差的健康狀況。此外，預算限制可能會限制醫療服務提供者開立最佳治療方法，這可能會阻礙市場成長潛力以及第二型糖尿病新型有效治療方法的創新。

全球第2型糖尿病市場趨勢

全球第2型糖尿病市場正經歷著向遠端監測和數位化醫療解決方案的重大轉變，這主要得益於穿戴式技術和行動應用程式的整合應用。這些創新使患者能夠持續監測血糖值，並與醫療服務提供者即時共用數據，從而實現主動疾病管理。更完善的血糖值追蹤、藥物順從性和整體健康管理不僅能改善病患預後，也有助於降低醫療成本。此外，這一趨勢提高了患者的參與度，最終將糖尿病護理轉變為更個人化和高效的體驗，也反映了醫療保健領域向科技融合的更廣泛趨勢。

目錄

介紹

• 調查目標
• 市場定義和範圍

調查方法

• 調查過程
• 二手資料和一手資料方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭格局概述

市場動態與展望

• 總體經濟指標
• 促進因素和機遇
• 限制與挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場考察

• 關鍵成功因素
• 影響市場的因素
• 關鍵投資機會
• 生態系測繪
• 市場吸引力指數（2025）
• PESTEL 分析
• 價值鏈分析
• 定價分析
• 案例研究
• 監管環境
• 技術評估

全球第2型糖尿病市場規模（依藥物類別及複合年成長率分類）（2026-2033年）

• Dipeptidyl Peptidase-4抑制劑
• 類升糖素肽-1受體促效劑
• 比瓜尼德斯
• 鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑
• 其他

全球第2型糖尿病市場規模（依給藥途徑及複合年成長率分類）（2026-2033年）

• 口服
• 腸外

全球第2型糖尿病市場規模（依通路分類）及複合年成長率（2026-2033年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球第2型糖尿病市場規模（依最終用戶分類）及複合年成長率（2026-2033年）

• 居家醫療環境
• 醫院和診所
• 學術和研究機構
• 其他

全球第2型糖尿病市場規模及複合年成長率（2026-2033年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Merck & Co., Inc.
• Boehringer Ingelheim
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Medtronic
• B. Braun Melsungen AG
• Abbott Laboratories
• F. Hoffmann-La Roche
• Insulet Corporation

結論與建議

Global Type 2 Diabetes Market size was valued at USD 36.7 Billion in 2024 and is poised to grow from USD 39.53 Billion in 2025 to USD 71.67 Billion by 2033, growing at a CAGR of 7.72% during the forecast period (2026-2033).

The global type 2 diabetes market is experiencing significant growth, primarily driven by the surging prevalence of the condition worldwide. This escalating demand for effective treatments has prompted pharmaceutical companies to innovate and introduce new therapies. Notable advancements include sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists, which have emerged as preferred options due to their efficacy and reduced side effects. However, a gap remains in patient awareness regarding these new treatments, potentially hindering their adoption. The increasing need for affordable and advanced diabetes management solutions creates substantial opportunities for market expansion. Furthermore, technological advancements, including mobile health applications and cloud-based solutions, are revolutionizing treatment delivery, making effective options more accessible to patients globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Type 2 Diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Type 2 Diabetes Market Segments Analysis

Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Distribution Channel, End User, and Region. Based on Drug Class, the market is segmented into Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Biguanides, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Based on End User, the market is segmented into Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Type 2 Diabetes Market

One of the key market drivers for the global Type 2 diabetes market is the increasing prevalence of obesity and sedentary lifestyles among populations worldwide. As obesity rates rise, the incidence of Type 2 diabetes escalates, prompting a growing demand for effective treatments and management solutions. This surge in cases is further fueled by genetic factors and dietary habits, leading to heightened awareness and proactive health measures. Consequently, pharmaceutical companies and healthcare providers are investing significantly in research and development of innovative therapies, monitoring devices, and educational programs, creating a robust market landscape focused on combating this chronic condition.

Restraints in the Global Type 2 Diabetes Market

One key market restraint for the global Type 2 diabetes market is the rising prevalence of drug affordability concerns among patients and healthcare systems. The increasing cost of diabetes management medications, including insulin and oral antidiabetic agents, poses significant barriers, particularly in low and middle-income regions. This financial strain can lead to non-adherence to prescribed treatments, ultimately resulting in poorer health outcomes. Moreover, healthcare providers may face limitations in prescribing optimal therapies due to budget constraints, thereby hindering the market's growth potential and innovation in new, effective treatment options for Type 2 diabetes.

Market Trends of the Global Type 2 Diabetes Market

The global Type 2 Diabetes market is experiencing a significant shift towards remote monitoring and digital health solutions, driven by the integration of wearable technologies and mobile applications. These innovations empower patients to continuously monitor their glucose levels and share real-time data with healthcare providers, fostering proactive disease management. Enhanced tracking of blood sugar levels, medication adherence, and overall health not only improves patient outcomes but also contributes to reduced healthcare costs. Furthermore, this trend stimulates increased patient engagement, ultimately transforming diabetes care into a more personalized and efficient experience, which reflects a broader movement towards technological integration in healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment

Global Type 2 Diabetes Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Dipeptidyl Peptidase-4 Inhibitors
• Glucagon-like Peptide 1 Receptor Agonists
• Biguanides
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
• Others

Global Type 2 Diabetes Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral

Global Type 2 Diabetes Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Type 2 Diabetes Market Size by End User & CAGR (2026-2033)

• Market Overview
• Homecare Settings
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Global Type 2 Diabetes Market Size & CAGR (2026-2033)

• North America (Drug Class, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Drug Class, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations